L01DB01 - search results

myocet 50 mg

medison pharma ltd - doxorubicin hydrochloride - powder,dispersion and solvent for concentrate for dispersion for infusion - doxorubicin hydrochloride 50 mg vials - doxorubicin - doxorubicin - myocet, in combination with cyclophosphamide, is indicated for the first line treatment of metastatic breast cancer in women.

Singapore - English - HSA (Health Sciences Authority)

caelyx concentrate for infusion 2 mgml

baxter healthcare (asia) pte ltd - doxorubicin hydrochloride - injection - 2.00 mg/ml - doxorubicin hydrochloride 2.00 mg/ml

Israel - English - Ministry of Health

caelyx

j-c health care ltd - doxorubicin hydrochloride - liposome concentrate for solution for infusion - doxorubicin hydrochloride 2.0 mg/ml - doxorubicin - doxorubicin - first or second line therapy of aids related kaposis sarcoma in patients with low cd 4 counts and extensive mucocutaneous or visceral disease the treatment of patients with metastatic carcinoma of the ovary who are refractory to both paclitaxel and platinium-based chemotherapy regimens and who may also be refractory to topotecan. refractory is defined as a patient having progressive disease while on treatment or within 6 months of completing treatmnt. as monotherapy for patients with metastatic breast cancer where there is an increased cardiac risk. in combination with bortezomib for the treatment of progressive multiplemyeloma in patients who have received at least one prior therapy and who have already undergone or are unsuitable for bone marrow transplant.

Ireland - English - HPRA (Health Products Regulatory Authority)

doxorubicin

accord healthcare limited - doxorubicin hydrochloride - concentrate for soln for inf - 2 mg/ml - doxorubicin

European Union - English - EMA (European Medicines Agency)

myocet liposomal (previously myocet)

teva b.v. - doxorubicin hydrochloride - breast neoplasms - antineoplastic agents - myocet liposomal, in combination with cyclophosphamide, is indicated for the first-line treatment of metastatic breast cancer in adult women.